Literature DB >> 10704751

Diminution of N-methyl-D-aspartate-induced perturbation of neurotransmission by dexmedetomidine in the CA1 field of rat hippocampus in vitro.

M Niittykoski1, A Haapalinna, J Sirviö.   

Abstract

The effects of alpha(2)-adrenoceptor activation on N-methyl-D-aspartic acid (NMDA)-induced perturbation of neurotransmission and normal NMDA-receptor dependent function (long-term potentiation, (LTP)) were investigated in the hippocampal CA1 field in vitro. Bath perfusion of dexmedetomidine hydrochloride (50 nM), which was initiated before NMDA (100 microM) exposure, enhanced the extent of recovery of extracellular field excitatory postsynaptic potentials after NMDA infusion. On the other hand, the induction and early maintenance of LTP was normal in the presence of dexmedetomidine. Thus, dexmedetomidine can diminish acute NMDA-induced perturbation of neurotransmission while the same dose of this drug does not influence the normal activation of NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704751     DOI: 10.1016/s0304-3940(00)00811-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Dexmedetomidine suppresses long-term potentiation in the hippocampal CA1 field of anesthetized rats.

Authors:  Ryoko Ito Kato; Kaori Tachibana; Toshikazu Hashimoto; Koichi Takita; Yuji Morimoto
Journal:  J Anesth       Date:  2014-05-23       Impact factor: 2.078

2.  The neuroprotective action of dexmedetomidine on apoptosis, calcium entry and oxidative stress in cerebral ischemia-induced rats: Contribution of TRPM2 and TRPV1 channels.

Authors:  Hatice Akpınar; Mustafa Nazıroğlu; İshak Suat Övey; Bilal Çiğ; Orhan Akpınar
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

Review 3.  Mechanisms of Dexmedetomidine in Neuropathic Pain.

Authors:  Yang Zhao; Jianshuai He; Ning Yu; Changxin Jia; Shilei Wang
Journal:  Front Neurosci       Date:  2020-05-05       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.